Efient (prasugrel hydrochloride) - Important Safety Information from Eli Lilly and Company Ltd. as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 03/12/2013

 

Problem Or Issue:
Important Safety Information communication from Eli Lilly and Company Ltd. on the increased risk of serious bleeding in Unstable Angina (UA)/NSTEMI patients when Efient (prasugrel hydrochloride) is administered prior to diagnostic coronary angiography.   

Important Safety Information ­- Efient (prasugrel hydrochloride)


« Back